Claims data shows among 60 028 psoriasis or psoriatic arthritis pts, there was NO significant difference in the risk of developing atrial fibrillation or major adverse cardiovascular events with ustekinumab (vs a TNF inhibitor) https://t.co/kJhUsmupLx